Claims
- 1. A compound of the formula: wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; n is an integer of 0-3; or a salt thereof.
- 2. A compound according to claim 1,wherein the ring A is a benzene ring which may be substituted by 1 or 2 substituents selected from the group consisting of halogen atom, hydroxy, C1-10 alkyl, C1-10 alkoxy, alkylenedioxy of the formula: —O—(CH2)m—O—; wherein m is an integer of 1-4, and C1-10 alkylthio; and R2 and R3 are independently hydrogen atom, C1-6 alkyl or phenyl.
- 3. A compound according to claim 1, wherein the ring A is a group of the formula: wherein R4 and R5 are independently hydrogen atom or C1-10 alkyl or R4 and R5 may be bound to each other to form a C1-4 alkylene chain; and R2 and R3 are independently hydrogen atom or C1-6 alkyl.
- 4. A compound according to claim 1, wherein the non-aromatic heterocyclic group of the optionally substituted non-aromatic heterocyclic group represented by R1 is a 5- to 6-membered non-aromatic heterocyclic group containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atom, sulfur atom and oxygen atom.
- 5. A compound according to claim 4, wherein the 5- to 6-membered non-aromatic heterocyclic group is one containing at least 1 nitrogen atom.
- 6. A compound according to claim 5, wherein the heterocycle of the 5- to 6-membered non-aromatic heterocyclic group is pyrrolidine, imidazolidine, thiazolidine, isothiazolidine, oxazolidine, oxadiazolidine, piperidine, piperazine, thiomorpholine or morpholine.
- 7. A compound according to claim 1, wherein the substituent or substituents in the optionally substituted non-aromatic heterocyclic group represented by R1 are 1 to 3 substituents selected from the group consisting of halogen atom, hydroxy or oxo, C1-10 alkyl, C1-6 alkoxy, C1-6 acyl, amino, mono- or di-C1-6 alkylamino, C1-6 alkylsulfonyl, carboxy and C1-6 alkoxy-carbonyl.
- 8. A compound according to claim 3, wherein R2 is a hydrogen atom; R3 is C1-3 alkyl; and R4 and R5 may be bound to each other to form a C1-2 alkylene chain.
- 9. A compound according to claim 3, wherein R2 and R3 are independently a hydrogen atom, and R4 and R5 are independently a C1-3 alkyl group.
- 10. N-[4-(4-Morpholinylmethyl)phenyl]-1,2,4,5-tetrahydro-7,8-methylenedioxy-4-methyl-5-oxo-3-benzothiepine-2-carboxamide,N-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenyl]-1,2,4,5-tetrahydro-7,8-methylenedioxy-4-methyl-5-oxo-3-benzothiepine-2-carboxamide, or N-[4-(2,4-dioxo-oxazolidin-5-ylmethyl)phenyl]-1,2,4,5-tetrahydro-7,8-methylenedioxy-4-methyl-5-oxo-3-benzothiepine-2-carboxamide, or a salt thereof.
- 11. A process for producing a compound of the formula: wherein the ring A is an optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently a hydrogen atom or an optionally substituted hydrocarbon group; and n is an integer of 0-3; or a salt thereof, which comprises reacting a compound of the formula: wherein each symbol has the same meanings as mentioned above; or a reactive derivative at the carboxy group thereof or a salt thereof, with a compound of the formula: wherein each symbol has the same meanings as mentioned above; or a reactive derivative at the amino group thereof or a salt thereof.
- 12. A prodrug of the compound according to claim 1, or a salt thereof.
- 13. A pharmaceutical composition comprisinga compound of the formula: wherein the ring A is a n optionally substituted benzene ring; R1 is an optionally substituted non-aromatic heterocyclic group; R2 and R3 are independently hydrogen atom or an optionally substituted hydrocarbon group; and n is an integer of 0-3; or a salt thereof; and a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
10-225065 |
Aug 1998 |
JP |
|
Parent Case Info
This application is a 371 of application Ser. No. PCT/JP99/04269, filed on Aug. 6, 1999.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/JP99/04269 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/08018 |
2/17/2000 |
WO |
A |
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5071841 |
Sohda et al. |
Dec 1991 |
A |
5158943 |
Sohda et al. |
Oct 1992 |
A |
5952512 |
Maeda et al. |
Sep 1999 |
A |
6190695 |
Hoshino et al. |
Feb 2001 |
B1 |
Foreign Referenced Citations (8)
Number |
Date |
Country |
0376197 |
Jul 1990 |
EP |
0460488 |
Dec 1991 |
EP |
0719782 |
Jul 1996 |
EP |
8-231569 |
Aug 1996 |
JP |
8601407 |
Mar 1986 |
WO |
9413642 |
Jun 1994 |
WO |
WO9639134 |
Dec 1996 |
WO |
WO9965474 |
Dec 1999 |
WO |
Non-Patent Literature Citations (2)
Entry |
Ahluwalia, et al., 1986, Indian J. Chem., 25B(5), 502-4.* |
Akiyama, et al. “TAK-778, a Novel Synthetic 3-Benzothiepin Derivative, promotes Chondrogenesis in Vitro and in Vivo” Biochemical and Biophysical Research Communications 261:131-138 (1999). |